Literature DB >> 18343632

Genomic expression patterns distinguish long-term from short-term glioblastoma survivors: a preliminary feasibility study.

Nicholas F Marko1, Steven A Toms, Gene H Barnett, Robert Weil.   

Abstract

We used microarray analysis to investigate associations between genotypic expression profiles and survival phenotypes in patients with primary glioblastoma (GBM). Tumor samples from 7 long-term glioblastoma survivors (>24 months) and 13 short-term survivors (<9 months) were analyzed to detect differential patterns of gene expression between these groups and to identify genotypic subclasses of glioblastomas that correlate with survival phenotypes. Five unsupervised and three supervised clustering algorithms consistently and accurately grouped the tumors into genotypic subgroups corresponding to the two clinical survival phenotypes. Three unique prospective mathematical classification algorithms were subsequently trained to use expression data to stratify unknown glioblastomas between survival groups and performed this task with 100% accuracy in validation studies. A set of 1478 genes with significant differential expression (p<0.01) between long-term and short-term survivors was identified, and additional mathematical filtering was used to isolate a 43-gene "fingerprint" that distinguished survival phenotypes. Differential regulation of a subset of these genes was confirmed using RT-PCR. Gene ontology analysis of the fingerprint demonstrated pathophysiologic functions for the gene products that are consistent with current models of tumor biology, suggesting that differential expression of these genes may contribute etiologically to the observed differences in survival. These results demonstrate that unique expression profiles characterize genotypic subsets of primary GBMs associated with differential survival phenotypes, and these profiles can be used in a prospective fashion to assign unknown tumors to survival groups. Future efforts will focus on building more robust classifiers and identifying additional subclasses of gliomas with phenotypic significance.

Entities:  

Mesh:

Year:  2008        PMID: 18343632     DOI: 10.1016/j.ygeno.2008.01.002

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  18 in total

1.  Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Authors:  Signe Regner Michaelsen; Thomas Urup; Lars Rønn Olsen; Helle Broholm; Ulrik Lassen; Hans Skovgaard Poulsen
Journal:  J Neurooncol       Date:  2018-01-05       Impact factor: 4.130

2.  Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.

Authors:  Andrew M Donson; Diane K Birks; Stephanie A Schittone; Bette K Kleinschmidt-DeMasters; Derrick Y Sun; Molly F Hemenway; Michael H Handler; Allen E Waziri; Michael Wang; Nicholas K Foreman
Journal:  J Immunol       Date:  2012-07-16       Impact factor: 5.422

3.  Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.

Authors:  Jonathan M Dreyfuss; Mark D Johnson; Peter J Park
Journal:  Mol Cancer       Date:  2009-09-04       Impact factor: 27.401

4.  Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo.

Authors:  Tatiana V Kolesnikova; Alexander R Kazarov; Madeleine E Lemieux; Marc A Lafleur; Santosh Kesari; Andrew L Kung; Martin E Hemler
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

5.  The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.

Authors:  Calin O Marian; Steve K Cho; Brian M McEllin; Elizabeth A Maher; Kimmo J Hatanpaa; Christopher J Madden; Bruce E Mickey; Woodring E Wright; Jerry W Shay; Robert M Bachoo
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

6.  Prognostic factors for long-term survival after glioblastoma.

Authors:  Mohammad Sami Walid
Journal:  Perm J       Date:  2008

7.  A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature.

Authors:  Pascal O Zinn; Pratheesh Sathyan; Bhanu Mahajan; John Bruyere; Monika Hegi; Sadhan Majumder; Rivka R Colen
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

8.  Long-Term Survival of a Patient with Giant Cell Glioblastoma: Case Report and Review of the Literature.

Authors:  E Naydenov; V Bussarsky; S Nachev; S Hadjidekova; D Toncheva
Journal:  Case Rep Oncol       Date:  2009-07-17

9.  Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study.

Authors:  James L Rogers; Elizabeth Vera; Alvina Acquaye; Nicole Briceno; Varna Jammula; Amanda L King; Heather Leeper; Martha M Quezado; Javier Gonzalez Alarcon; Lisa Boris; Eric Burton; Orieta Celiku; Anna Choi; Alexa Christ; Sonja Crandon; Ewa Grajkowska; Nicole Leggiero; Nicole Lollo; Marta Penas-Prado; Jennifer Reyes; Christine Siegel; Brett J Theeler; Michael Timmer; Kathleen Wall; Jing Wu; Kenneth Aldape; Mark R Gilbert; Terri S Armstrong
Journal:  Neurooncol Pract       Date:  2021-04-10

10.  Identification and characterization of alternative exon usage linked glioblastoma multiforme survival.

Authors:  Ahmed Sadeque; Nicola Vl Serão; Bruce R Southey; Kristin R Delfino; Sandra L Rodriguez-Zas
Journal:  BMC Med Genomics       Date:  2012-12-04       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.